A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma

The aim of this study is to compare the efficacy and safety of YIV-906 plus standard-of-care sorafenib versus those of sorafenib alone as a first-line systemic treatment for patients with Hepatitis B (+) associated advanced hepatocellular carcinoma.
YIV-906 (PHY906, KD018) is an immune system modulator. Clinical and preclinical research suggests that YIV-906 could act to enhance the body's immune response to fight cancer and increase the anti-tumor activity of sorafenib and protect and repair the gastrointestinal tract by reducing inflammation and promoting tissue regeneration.
Inspired by a 1,800-year-old traditional medicine still in use today, YIV-906 is a botanical drug candidate, composed of an extract of four herbs and administered in oral capsule form.
The CALM (Combination of YIV-906 and Sorafenib to treat Advanced Liver cancer in a Multi-center study) trial is a multi-regional, randomized, placebo-controlled study.

开始日期2020-01-10

申办/合作机构

Yiviva, Inc.

NCT02178644

/ Completed临床1期IIT

Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer

This pilot study focuses on KD018 and will investigate the effect of this agent on reducing the Gastrointestinal (GI) toxicity associated with combined modality therapy of locally-advanced rectal cancer.

开始日期2014-07-01

申办/合作机构

Yale University

NCT00730158

/ Completed临床2期IIT

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

The proposed plan will investigate the mechanism and efficacy of Chinese herbal medicine as an adjunct to chemotherapy in treatment of patients with metastatic colorectal cancer. Our rationale for the therapeutic use of KD018 is its potential activity in reducing chemotherapy-induced toxicity, especially diarrhea.

开始日期2008-12-01

申办/合作机构

University of Pittsburgh

[+1]

100 项与 YIV-906 相关的临床结果

登录后查看更多信息

100 项与 YIV-906 相关的转化医学

登录后查看更多信息

100 项与 YIV-906 相关的专利（医药）

登录后查看更多信息

项与 YIV-906 相关的文献（医药）

2024-06-01·Journal of Gastrointestinal Oncology

A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer

Article

作者: Liu, Shwu-Huey ; Higgins, Susan A ; Lam, Wing ; Hochster, Howard ; Zaheer, Wajih ; Cheng, Yung-Chi ; Johung, Kimberly L ; Kortmansky, Jeremy ; Lacy, Jill ; Verma, Nipun ; Cecchini, Michael ; Stein, Stacey ; Reddy, Vikram

Background:

Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether the addition of YIV-906, a novel herbal medicine proven to reduce GI toxicity associated with chemotherapy could also reduce GI side effects during standard pre-operative capecitabine and pelvic radiation therapy (RT) in the neoadjuvant setting for the treatment of locally advanced rectal cancer.

Methods:

This single arm clinical study enrolled 24 patients between Dec 23, 2014-Sep 17, 2018 at Smilow Cancer Hospital, a comprehensive cancer center at Yale New Haven Hospital. All patients were age ≥18 years, Eastern Cooperative Oncology Group 0-1 and with histologically confirmed T3-T4 and N0-N2, M0 adenocarcinoma of the rectum. Median follow-up was 61.9 months. All patients received concurrent pelvic external beam RT (50.4 Gy in 28 fractions), YIV-906 (taken orally 800 mg twice daily on days 1-4 of RT each week), and oral capecitabine delivered in a neo-adjuvant fashion, followed by definitive surgery. Toxicity was assessed weekly during radiation and until acute symptoms resolved and then at 28 days, 4 months, 7 months and 10 months. Toxicities were graded in accordance with Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Results:

At the time of surgery, 4 patients (16.7%) had a complete or near-complete response. At a median follow-up of 61.9 months, the mean overall survival (OS) of our patient cohort was 74.9 months [95% confidence interval (CI): 67.3-82.5]. The estimated 5-year OS was 82.0%. We observed 0% acute grade 4 toxicities, and only two cases of acute grade 3 diarrhea (8.3%).

Conclusions:

The addition of YIV-906 to capecitabine based chemoradiation for locally advanced rectal cancer led to reduced rates of GI toxicity compared to historical controls, in particular grade 3 or greater diarrhea. These findings suggest YIV-906 should be evaluated in a randomized clinical trial to further assess potential reductions in the toxicity profile of chemoradiation for GI cancers.

2024-01-01·Integrative cancer therapies

Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis

Review

作者: He, Bing ; Zhang, Wei ; He, Yanxi ; Xiong, Xia ; Qi, Xiaoyi ; Liang, Sicheng ; Wang, Yu ; Wang, Xuan ; Deng, Mingming ; Wu, Lili ; Zhao, Wenjing

Background::

Irinotecan is widely used in the treatment of various solid tumors, but the adverse effects from it, especially diarrhea, limit its use. Several clinical trials of prophylactic treatment of irinotecan-induced diarrhea (IID) have been ongoing, and some of the data are controversial. This encouraged us to conduct a meta-analysis of the effects of interventions on preventing IID.

Method::

This systematic review was conducted based on the PRISMA statement. We performed literature searches from PubMed, Web of Science, Embase, and Cochrane Library. The number registered in PROSPERO is CRD42022368633. After searching 1034 articles in the database and references, 8 studies were included in this meta-analysis.

Result::

The RR of high-grade diarrhea and all-grade diarrhea were 0.31 ( I2 = 51%, 95% CI: 0.14-0.69; P = .004) and .76 ( I2 = 65%, 95% CI: 0.62-0.93; P < .008) respectively, thus the use of intervention measures for preventing IID is effective, and the risk reduction of high-grade diarrhea was more significant. Subgroup analysis revealed that the monotherapy group (RR: 0.48, 95% CI: 0.21-1.13, I2 = 0%) and combination therapy group (RR: 0.14, 95% CI: 0.06-0.32, I2 = 0%) in the risk of high-grade diarrhea had no significant heterogeneity within the groups, and traditional herbal medicines (Kampo medicine Hangeshashin-to, PHY906 and hot ironing with Moxa Salt Packet on Tianshu and Shangjuxu) were effective preventive measures (RR:0.20, 95% CI: 0.07-0.60, I2 = 0%). The Jadad scores for traditional herbal medicines studies were 3, and the follow-up duration was only 2 to 6 weeks.

Conclusion::

This systematic review and meta-analysis suggest that preventive treatments significantly reduced the risk of high-grade and all-grade diarrhea, confirming the efficacy in the incidence and severity of IID, among which traditional herbal medicines (baicalin-containing) provided a protective effect in reducing the severity of IID. However, the traditional herbal medicines studies were of low quality. Combined irinotecan therapy can obtain better preventive effects than monotherapy of IID. These would be helpful for the prevention of IID in clinical practice.

2021-05-01·Chinese journal of natural medicines

A four-component combination derived from Huang-Qin Decoction significantly enhances anticancer activity of irinotecan

Article

作者: Wan, Jian-Bo ; Xu, Dou-Dou ; Xu, Feng-Guo ; Hou, Xiao-Ying ; Wang, Ou ; Wang, Di ; Zhang, Zun-Jian ; Qin, Si-Yuan ; Dai, Xiao-Min ; Li, Dan-Ting ; Lv, Bo

Huang-Qin Decoction (HQD) is a classic prescription for diarrhea in Chinese medicine treatment. Recent studies have demonstrated that HQD and its modified formulation PHY906 could ameliorate irinotecan (CPT-11) induced gastrointestinal (GI) toxicity and enhance its anticancer therapeutic efficacy. Nevertheless, which constituents in HQD are effective is still unclear so far. The study aims to screen out the key bioactive components combination from HQD that could enhance the anticancer effect of CPT-11. First, the potential bioactive constituents were obtained through system pharmacology strategy. Then the bioactivity of each constituent was investigated synthetically from the aspects of NCM460 cell migration, TNF-α release of THP-1-derived macrophage and MTT assay in HCT116 cell. The contribution of each constituent in HQD was evaluated using the bioactive index E_i, which taken the content and bioactivity into comprehensive consideration. And then, the most contributing constituents were selected out to form a key-component combination. At last, the bioefficacy of the key-component combination was validated in vitro and in vivo. As a result, a key-component combination (HB4) consisting of four compounds baicalin, baicalein, glycyrrhizic acid and wogonin was screened out. In vitro assessment indicated that HB4 could enhance the effect of CPT-11 on inhibiting cell proliferation and inducing apoptosis in HCT116. Furthermore, the in vivo study confirmed that HB4 and HQD have similar pharmacological activity and could both enhance the antitumor effect of CPT-11 in HCT116 xenograft model. Meanwhile, HB4 could also reduce the CPT-11 induced GI toxicity.

项与 YIV-906 相关的新闻（医药）

2025-07-10

·GlobeNewswire-Health Care

Yiviva Presents Phase 2b Results for YIV-906 in Combination with Sorafenib in Advanced Hepatocellular Carcinoma at ASCO and ESMO GI 2025

July 07, 2025 -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, double-blind, placebo-controlled Phase 2b study of sorafenib (SORA) with or without YIV-906 in advanced hepatocellular carcinoma (HCC) patients with chronic hepatitis B (HBV+). Results were highlighted in an American Society of Clinical Oncology (ASCO) Annual Meeting (May 30-June 3) abstract and presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress 2025 (July 2-July 5) poster. Presented by Dr. Ghassan Abou-Alfa MD, JD, MBA, PhD(hc), medical oncologist at Memorial Sloan Kettering Cancer Center, the study demonstrated improvements in both efficacy and tolerability for patients treated with YIV-906 plus sorafenib versus sorafenib monotherapy. 4.1 months vs. 3.5 months in the intention-to-treat (ITT) analysis Median Overall Survival (mOS): 14.3 months vs 7.5 months Median Time to Tumor Progression (mTTP): 5.59 months vs. 2.33 months Safety and Tolerability: Patients on the YIV-906 arm patients demonstrated greater duration of treatment exposure and continuation and were able to remain on treatment longer More than 250 GI (liver, pancreatic, colorectal, rectal) cancer patients treated in YIV-906 clinical studies have demonstrated proof-of-concept efficacy and safety. YIV-906 is a novel multi-targeted modality developed using a systems biology approach. YIV-906 increases the therapeutic index by acting as an immunomodulator in the tumor microenvironment (TME) and potentiating antitumor activity YIV-906 reprograms and primes the TME (STING, IFNg, IFNb, P-IRF3) and enhances innate immunity by polarizing and increasing M1 like macrophage infiltration and enhancing apoptosis. YIV-906 enhances adaptive immunity by promoting T-cell activation (promoting NFAT, inhibiting SHP1 and SHP2), modulating immune checkpoints (PD1/PDL1), reducing immune tolerance (by suppressing IDO), YIV-906 increases safety and reduces non-hematological toxicities by cytoprotecting the gastrointestinal tract by reducing GI inflammation (NF-kB, COX2, iNOS, IL-6), promoting damaged tissue repair (Wnt pathway), and reducing pain (NK1). “These results demonstrate the obligation to further study YIV-906’s potential to benefit hepatocellular carcinoma patients with hepatitis B who have limited treatment options,” said co-principal investigator Prof. Dr. Ghassan Abou-Alfa. “YIV-906 could broaden the therapeutic index and improve efficacy, safety and tolerability, and merits further clinical exploration with other studies and standards-of-care as a potential new treatment modality and paradigm.” The Phase 2b study (NCT04000737) randomized (2:1) patients (n=62) with treatment-naïve, advanced HBV-positive HCC, Child-Pugh A, BCLC Stage B or C, and ECOG ≤1 to either the YIV-906 + sorafenib arm or the placebo + sorafenib arm. Patients were enrolled in multiple regions (United States, Mainland China, Hong Kong, Taiwan) and the study was conducted from January 2020 to November 2024. The primary endpoint was progression free survival (PFS); secondary endpoints included overall survival (OS), time to progression (TTP), objective response rate (ORR), diseases control rate (DCR), safety and tolerability, and quality of life (QoL). More detailed information is available through 2025 ASCO Abstract # e16244 and ESMO GI Poster #P172. The study was sponsored by Yiviva with grant support from the Henry Bronson Endowment of Yale University, National Foundation for Cancer Research, Asian Fund for Cancer Research, and China 13-5 National Major Scientific and Technological Special Project for Significant New Drug Development. YIV-906 (formerly known as PHY906 or KD018) is a patented, orally administered investigational drug that acts as a pan-adjuvant improving the efficacy and safety for a broad spectrum of cancer drugs and regimens (including chemotherapies, immunotherapies, radiation, and cell therapies). YIV-906 has been studied in nine clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancer) with data demonstrating the potential for YIV-906 to improve overall survival and/or progression-free survival and reduce non-hematological toxicities (including diarrhea, nausea, vomiting, fatigue, and hand-foot syndrome). YIV-906 was inspired by an 1800-year-old traditional medicine and is being developed under the United States Food and Drug Administration’s (FDA) botanical drug regulatory pathway. The FDA has granted YIV-906 two Orphan Drug Designations (ODD) for the treatment of hepatocellular carcinoma and pancreatic cancers. Yiviva is committed to developing innovative medicines using a multi-targeted systems biology approach to improve survival and quality of life for patients with cancer and other serious diseases. The platform biotechnology company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Asia. The content above comes from the network. if any infringement, please contact us to modify.

临床结果孤儿药ASCO会议免疫疗法

2024-08-13

·drugs

Chinese Botanical Medicine Eases a Cancer Treatment Side Effect

TUESDAY, Aug. 12, 2024 -- An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results suggest. A small group of 24 patients experienced fewer GI side effects from their treatment for rectal cancer after they took YIV-906, researchers reported recently in the Journal of Gastrointestinal Oncology . YIV-906 is based on an 1,800-year-old treatment for stomach ailments that combined licorice, dates, peonies and skullcap, researchers said. “This study is the first demonstration of YIV-906’s effectiveness in reducing GI toxicity caused by chemotherapy and radiation, showing the medicine’s potential of improving the patient’s quality of life while increasing treatment effectiveness,” said co-researcher Yung-Chi Cheng , a professor of pharmacology at Yale School of Medicine who helped develop the drug. For the four-year, phase 2 study, the patients were given capsules of YIV-906 along with chemo and radiation prior to surgery. At the time of surgery, about 17% of patients had a complete or near-complete response to their cancer treatment, while the overall survival rate at five years was 82%, results show. Only two cases of severe diarrhea were reported among the patients. YIV-906 is meant to ease side effects like diarrhea, fatigue and nausea. “We didn’t have any serious toxicity associated with the drug and patients found taking the drug in pill form very easy and tolerable,” senior researcher Dr. Susan Higgins , a professor of therapeutic radiology and of obstetrics, gynecology, and reproductive sciences at Yale. The results warrant further testing of YIV-906 in more patients with other types of cancer, such as pelvic cancer, researchers said in a Yale new release. People taking YIV-906 might be able to withstand harsher doses of both chemo and radiation therapy, making their cancer treatment more effective, the researchers added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果放射疗法临床2期

2024-02-05

·GlobeNewswire-Health Care

Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International Import Expo (CIIE) at the National Exhibition and Convention Center in Shanghai. To address global unmet medical needs, Together Yiviva and AstraZeneca China will jointly build platforms for scientific research transformation and industrial development led by academicians and experts with the aim to modernize botanical medicines in accordance with new regulatory pathways for botanical medicines by the United States Food and Drug Administration (FDA) and China National Medical Products Administration (NMPA). “2023 marks the 30th anniversary of AstraZeneca in China. In collaboration with the Chengdu government and Chengdu High-Tech Industrial Zone (CDHT), AstraZeneca is establishing a modern healthcare development platform integrating traditional Chinese medicine and Western medicine. At CIIE, AstraZeneca announced plans to further globalize Chinese medicine. Our strategic partnership with Yiviva, will advance our blueprint for how to develop innovative medicines inspired by Chinese medicine,” remarked Lily Zhu, Vice President of AstraZeneca China and Head of DCI and CSE. “Disease knows no borders. By bringing together the knowledge and best practices of Western and Eastern Medicine, WE Medicine, we can learn from ancient wisdom to develop future medicines. Together with AstraZeneca China’s expertise, ecosystem, and resources, and Yiviva’s team, platform technologies, and pipeline, we can pioneer a new paradigm for systems biology drug development to address global unmet medical needs,” said Peikwen Cheng, Co-Founder and CEO of Yiviva. About Yiviva’s Platforms and Pipeline in Oncology Yiviva’s STAR (signal transduction, activity and response) drug discovery platform accelerates the identification of botanical therapeutics that influence immune function, inflammatory responses, cell growth, metabolic functions, and hormone activity. Through STAR, Yiviva can design sophisticated multi-target drugs that map to complicated disease biology. Yiviva has discovered six first-in-class drug candidates to treat cancer and inflammatory diseases. Yiviva applies patented, mechanism-based quality control linked to biological activity to manufacture batch-to-batch consistent drug product that satisfies established regulatory requirements for complex products. Yiviva’s lead candidate drug YIV-906 is a proprietary extract of 4 medicinal plants, inspired by an 1800-year-old traditional Chinese medicine formula. YIV-906 acts as an immunomodulator in the tumor microenvironment, turning cold tumors hot and potentiating anti-tumor activity for chemotherapies, immunotherapies, cell therapies, or radiation therapies; and acts as a cytoprotector in the gastrointestinal tract, reducing non-hematological toxicities and speeding up damaged tissue recovery. Yiviva has conducted 8 early-stage clinical trials in solid tumors (hepatocellular carcinoma, pancreatic cancer, colorectal cancer, and rectal cancers), with promising data suggesting that YIV-906 could prolong survival and improve quality of life. Yiviva recently recruited its last-patient-in in a first-line, randomized, double-blinded Phase 2b study of sorafenib plus YIV-906 in the treatment of hepatocellular carcinoma patients with hepatitis B. The CALM study is a multi-regional trial in the United States, Mainland China, Hong Kong, and Taiwan and expects a data readout in 2024. Yiviva recently published preclinical data conducted at Yale University about its novel therapeutic YIV-818-A to treat prostate cancer. YIV-818-A acts through multiple mechanisms, including androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation and could help overcome drug resistance to prostate cancer and could enhance apalutamide, darolutamide, or enzalutamide efficacy. About Yiviva Yiviva is a clinical stage, platform biotechnology company developing systems biology medicines to prevent, treat, and/or cure aging-related diseases, including cancer and inflammatory diseases. The company was launched with Yale University and Henry Bronson Professor of Pharmacology and Medicine Yung-Chi Cheng as co-founders, with teams in the United States and Greater China. Yiviva’s investors include the National Foundation for Cancer Research and the Asian Fund for Cancer Research. For further information, please visit https://yiviva.com. About AstraZeneca AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca. Contact:Email: hello@yiviva.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8d78fdf0-e819-4a98-abe1-3944978b9ad8

临床2期免疫疗法

100 项与 YIV-906 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	临床2期	美国	Yale University	2022-06-15
晚期肝细胞癌	临床2期	美国	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国香港	Yiviva, Inc.	2020-01-10
晚期肝细胞癌	临床2期	中国台湾	Yiviva, Inc.	2020-01-10
转移性结直肠癌	临床2期	美国	Kadmon Corp. LLC	2008-12-01
转移性胰腺腺癌	临床2期	美国	PhytoCeutica, Inc.	2006-12-01
转移性胰腺腺癌	临床2期	美国	Roche Pharma AG	2006-12-01
不可切除的肝细胞癌	临床2期	美国	PhytoCeutica, Inc.	2003-10-01
不可切除的肝细胞癌	临床2期	中国台湾	PhytoCeutica, Inc.	2003-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04000737 (International phase II randomized placebo-controlled study, ASCO2025)	临床2期	晚期肝细胞癌一线 HBV (+)	107	YIV-906 + Sorafenib	簾餘艱選製窪簾製鑰齋(鹽夢選遞製餘餘憲築獵) = improvement was also observed by the investigator 醖餘蓋蓋築選積餘願範 (糧願簾鏇襯餘積窪糧淵 ) 更多	积极	2025-05-30
				Placebo
NCT00730158 (CTgov)	临床2期	转移性结直肠癌	33	Irinotecan+KD018 (Arm A - Irinotecan + KD018)	淵製廠鑰糧願夢餘鏇構 = 醖膚膚糧遞淵簾憲構廠鑰網糧壓餘觸範窪憲窪 (衊繭窪獵夢壓網願襯繭, 鑰壓衊糧齋廠顧鬱觸製 ~ 鑰襯鏇夢鏇製憲鏇築蓋) 更多	-	2019-05-22
				Placebo+Irinotecan (Arm B - Irinotecan + Placebo)	淵製廠鑰糧願夢餘鏇構 = 構蓋製遞築醖觸鏇夢醖鑰網糧壓餘觸範窪憲窪 (衊繭窪獵夢壓網願襯繭, 衊齋遞淵壓夢廠範顧鹹 ~ 鑰餘獵顧鬱鏇廠網鏇壓) 更多
NCT00411762 (CTgov)	临床1/2期	转移性胰腺腺癌 \| 胰腺癌	25	Capecitabine+PHY906	餘衊築觸壓遞範餘衊襯(齋願網淵觸顧醖膚網蓋) = 鬱鑰願夢窪夢憲願糧觸鬱獵齋衊艱窪夢夢繭鏇 (膚鬱膚齋選餘憲淵網醖, 蓋觸窪壓鹽鑰願遞齋壓 ~ 憲鏇鬱網範窪鑰餘蓋醖) 更多	-	2015-03-27
NCT04000737 (Pubmed \| Cancer Chemother Pharmacol)	临床2期	胰腺癌二线	25	Capecitabine + PHY906	顧獵蓋簾夢網壓襯廠構(憲襯蓋衊壓醖夢顧艱糧) = 構選繭淵製糧觸鏇顧鹽構齋鬱觸範願遞鏇壓廠 (鹹構繭顧淵夢膚觸積艱 ) 更多	-	2014-02-01
ASCO2010	临床2期	胰腺癌	25	PHY906 plus capecitabine (CAP)	壓蓋齋顧網鏇鬱選積鬱(製鹹製簾壓製網願夢築) = 鏇襯窪夢窪構獵鹽夢蓋壓廠襯襯廠構糧鏇膚構 (繭觸衊餘壓築淵鑰願艱 ) 更多	-	2010-05-20
NCT04000737 (Pubmed)	临床1/2期	晚期肝细胞癌	-	PHY906	鏇鹹願襯構積鑰衊餘積(醖選觸餘鏇鹽鏇醖範壓) = 壓繭齋鬱築獵蓋獵襯襯製積齋憲齋窪鹽夢鏇夢 (簾憲齋壓選簾構構獵衊 ) 更多	-	2009-10-01
ASCO2009	N/A	胃肠道肿瘤	44	PHY906	製築衊製鹽衊衊鑰廠鹹(壓觸製醖遞鬱衊艱願醖) = 齋獵選蓋鑰繭遞窪構鏇繭廠網蓋醖鹹膚廠窪製 (壓築鬱蓋範選窪廠壓襯 )	-	2009-05-20
				CAP alone	製築衊製鹽衊衊鑰廠鹹(壓觸製醖遞鬱衊艱願醖) = 齋鹽壓齋餘獵願築網製繭廠網蓋醖鹹膚廠窪製 (壓築鬱蓋範選窪廠壓襯 )
ASCO2007	临床1/2期	肝细胞癌	18	PHY906 + Capecitabine 1000 mg/m2 BID	鹹簾廠糧願壓襯糧製艱(壓淵構齋願餘範鬱鹹窪) = 願窪遞窪鏇選壓醖醖範壓願憲顧顧鹹廠夢築獵 (襯鹹鏇齋簾鬱築襯膚製 ) 更多	-	2007-06-20
				PHY906 + Capecitabine 750 mg/m2 BID	鹹簾廠糧願壓襯糧製艱(壓淵構齋願餘範鬱鹹窪) = 顧糧廠淵鑰積獵壓鑰選壓願憲顧顧鹹廠夢築獵 (襯鹹鏇齋簾鬱築襯膚製 ) 更多